SCHEMBL4954263

SCHEMBL4954263

O=C(Cl)c1cc([N+](=O)[O-])ccc1O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.63
ALDH1A1 P00352 5/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
TSHR P16473 3/20 0.56
GPR35 Q9HC97 2/20 0.56
TP53 P04637 2/20 0.56
MAPK1 P28482 2/20 0.56
HPGD P15428 1/20 0.56
GAA P10253 2/20 0.55
THRB P10828 1/20 0.55
ERN1 O75460 1/20 0.51
KCNMA1 Q12791 2/20 0.51
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
NPC1 O15118 2/20 0.50
MAPT P10636 2/20 0.50
PKM P14618 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
AURKA O14965 1/20 0.50
PDPK1 O15530 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1644789 0.85 GPR35 (0.56) L3MBTL1ALDH1A1SMN1; SMN2TSHRGPR35
SCHEMBL27129636 0.85 L3MBTL1 (0.67) L3MBTL1ALDH1A1SMN1; SMN2TSHRGPR35
SCHEMBL10694655 0.85 ALDH1A1 (0.57) L3MBTL1ALDH1A1SMN1; SMN2TSHRGPR35
SCHEMBL19490033 0.84 L3MBTL1 (0.57) L3MBTL1ALDH1A1SMN1; SMN2TSHRGPR35
SCHEMBL30322798 0.83 ALDH1A1 (0.69) L3MBTL1ALDH1A1SMN1; SMN2TSHRGPR35
SCHEMBL129889 0.83 ALDH1A1 (0.69) L3MBTL1ALDH1A1SMN1; SMN2TSHRGPR35
SCHEMBL6393919 0.81 ALDH1A1 (0.67) L3MBTL1ALDH1A1SMN1; SMN2TSHRGPR35
SCHEMBL4639633 0.81 L3MBTL1 (0.63) L3MBTL1ALDH1A1SMN1; SMN2TSHRGPR35
SCHEMBL6393916 0.81 L3MBTL1 (0.63) L3MBTL1ALDH1A1SMN1; SMN2TSHRGPR35
SCHEMBL8410965 0.81 ALDH1A1 (0.67) L3MBTL1ALDH1A1SMN1; SMN2TSHRGPR35

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116334195-A Space single cell transcriptome sequencing method based on light-controlled cell markers 北京大学 2023-06-27 CN claimed
CN-119894878-A Aromatic amide derivative and preparation method and application thereof 浙江海正药业股份有限公司 2025-04-25 CN disclosed
CN-118108621-A Diamine compound, heat-resistant resin, resin composition, cured film, and electronic component 东友精细化工有限公司 2024-05-31 CN disclosed
WO-2024078569-A1 AROMATIC AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF 浙江海正药业股份有限公司 2024-04-18 WO disclosed
CN-116334195-A Space single cell transcriptome sequencing method based on light-controlled cell markers 北京大学 2023-06-27 CN disclosed
EP-2774914-B1 N-BENZYLANILINE DERIVATIVE AND USES THEREOF UNIV NANJING MEDICAL (CN) 2017-12-06 EP disclosed
CN-103992336-B Oxa-or thia evodiamine anti-tumor derivant and preparation method thereof 中国人民解放军第二军医大学 2017-01-04 CN disclosed
US-9481636-B2 N-benzylaniline derivative and uses thereof NANJING MEDICAL UNIVERSITY (CN) 2016-11-01 US disclosed
US-20140303248-A1 N-BENZYLANILINE DERIVATIVE AND USES THEREOF Neurodawn Pharmaceutical Co., Ltd. (CN) 2014-10-09 US disclosed
EP-2774914-A1 N-BENZYLANILINE DERIVATIVE AND USES THEREOF Nanjing Medical University (CN) 2014-09-10 EP disclosed
US-7462735-B2 Amino acid diamides in non α position which are useful as adjuvants for administration of biological active agents LABORATORIOS FARMACEUTICOS ROVI, S.A. (ES) 2008-12-09 US disclosed
US-20070191302-A1 AMINO ACID DIAMIDES IN NON ALPHA POSITION WHICH ARE USEFUL AS ADJUVANTS FOR ADMINISTRATION OF BIOLOGICAL ACTIVE AGENTS LABORATORIOS FARMACEUTICOS ROVI S.A. (ES) 2007-08-16 US disclosed
EP-1652836-B1 AMINO ACID DIAMIDES IN NON ALPHA POSITION USEFUL AS ADJUVANTS FOR THE ADMINISTRATION OF ACTIVE BIOLOGICAL AGENTS ROVI LAB FARMACEUT SA (ES) 2007-07-18 EP disclosed
CN-1829682-A Amino acid diamides in non-alpha positions useful as adjuvants for the administration of biologically active agents ROVI LAB FARMACEUT SA (ES) 2006-09-06 CN disclosed
EP-1652836-A1 AMINO ACID DIAMIDES IN NON ALPHA POSITION USEFUL AS ADJUVANTS FOR THE ADMINISTRATION OF ACTIVE BIOLOGICAL AGENTS LABORATORIOS FARMACEUTICOS ROVI, S.A. (ES) 2006-05-03 EP disclosed
US-20050124664-A1 Urea thiadiazole inhibitors of plasminogen activator inhibior-1 BRISTOL-MYERS SQUIBB CO. 2005-06-09 US disclosed
US-20050113438-A1 Substituted indoles WYETH (US) 2005-05-26 US disclosed
US-4578499-A CHEMILUMINESCENT REAGENTS WAKO PURE CHEMICAL INDUSTRIES LTD. (JP) 1986-03-25 US disclosed
US-4350692-A CEPHALOSPORINS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-09-21 US disclosed
US-4146631-A ANTIALLERGENS, RESPIRATORY DISORDERS MAY & BAKER LIMITED (GB) 1979-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124664-A1 Urea thiadiazole inhibitors of plasminogen activator inhibior-1 SERPINE1, SERPINC1, SERPINB1 L3MBTL1 2991/4885ALDH1A1 155/4885SMN1; SMN2 3158/4885
US-20050113438-A1 Substituted indoles IDO2, IDO1, INMT L3MBTL1 1992/4885ALDH1A1 414/4885SMN1; SMN2 3610/4885
US-20070191302-A1 AMINO ACID DIAMIDES IN NON ALPHA POSITION WHICH ARE USEFUL AS ADJUVANTS FOR ADMINISTRATION OF BIOLOGICAL ACTIVE AGENTS NOS1, NOS3, ARG1 L3MBTL1 3096/4885ALDH1A1 1095/4885SMN1; SMN2 3766/4885
US-20140303248-A1 N-BENZYLANILINE DERIVATIVE AND USES THEREOF NLN, INA, TRPV1 L3MBTL1 3659/4885ALDH1A1 1015/4885SMN1; SMN2 425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.